This week's roundup of Houston innovators includes Isabella Schmitt of Proxima Clinical Research, Rob Schapiro of Microsoft, and Lara Cottingham of Greentown Labs. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from medical device innovation to energy tech— recently making headlines in Houston innovation.

Isabella Schmitt, director of regulatory affairs at Proxima Clinical Research and principal at M1 MedTech

A Houston life science expert shares what she thinks Houston needs to work on to continue growing as an health care innovation ecosystem. Photo courtesy

Houston is home to the world's largest medical center, but it still tends to fall behind other metros when it comes to life science innovation hub rankings. Isabella Schmitt, director of regulatory affairs at Proxima Clinical Research and principal at M1 MedTech, writes in a guest column for InnovationMap about why this is — and what can be done to change that.

"Houston's life sciences sector holds immense growth potential, but addressing funding, talent recruitment, regulatory navigation, and collaboration challenges is needed for continued success," she writes. "By tackling these issues and leveraging its unique strengths, Houston can establish itself as a significant player in the global life sciences arenas. If we wait too long, we won’t be able to truly establish the Third Coast because another player will come into the mix, and we’ll lose companies like BioMatrix to their golden shores." Read more.

Rob Schapiro, Energy Acceleration Program director and Houston site leader for Microsoft

Rob Schapiro of Microsoft joins the Houston Innovators Podcast to discuss DEI initiatives, translating between the tech in the energy sectors, AI, and more. Photo courtesy of Microsoft

At a glance, Rob Schapiro admits his resume might not make the most sense. A trained geologist with decades of experience in the energy sector, Schapiro made the move to Microsoft three years ago.

"I saw this disconnect between technology companies and energy companies — they didn't really speak the same language," he says on this week's episode of the Houston Innovators Podcast. "I thought I could help potentially solve this problem and work between the two as a sort of translator."

Now, as Microsoft’s Energy Acceleration Program director and site leader for the company’s Houston office, which is located in the Ion, Schapiro is deeply embedded in Houston's innovation ecosystem and is dedicated to helping advance Houston's role energy transition in a sustainable and equitable way. Read more.

Lara Cottingham, vice president of strategy, policy, and climate impact at Greentown Labs

Greentown Houston is asking its current and potential members what they want in a wet lab. Photo via GreentownLabs.com

Greentown Labs is in the early stages of building out a wet lab for its members. But first, Lara Cottingham, vice president of strategy, policy, and climate impact at Greentown Labs, says they want to know what their members actually want.

"We want to announce to the community that this is something we're going to build — but we still need a lot of feedback and input from startups so we can learn what exactly they need or want to see from the wet lab," Cottingham tells InnovationMap. "No two wet labs are the same."

Right now, there aren't any details available about timeline or specifics of the new facility. Greentown is prioritizing getting feedback from its members and having conversations with potential sponsors and corporate partners. Read more.

A Houston life science expert shares what she thinks Houston needs to work on to continue growing as an health care innovation ecosystem. Photo via Getty Images

Expert: Houston has potential to be a major hub for life sciences — if it addresses these concerns

guest column

Once upon a time in Houston, a promising startup, let’s call it BioMatrix, set out to revolutionize the world of biomaterials. Their groundbreaking product held immense potential, but the company faced the harsh reality of a lack of funding, resources, and talent in their local life sciences sector.

As they watched well-funded competitors in established hubs like Boston and Silicon Valley flourish, the passionate team at BioMatrix persevered, determined to overcome these challenges, and make their mark in the rapidly evolving world of MedTech and life sciences. But would they ultimately move to a richer life science hub?

Over the years, Houston has emerged as a life sciences hub, fueled by the world's largest medical center, Texas Medical Center, and an expanding network of research institutions, startups, and investors. However, despite all its potential, the city still lags other innovation hubs and isn’t included in many of the lists for top life science ecosystems. The challenges are many-fold, but some primary challenges are associated with lack of capital, trouble with talent acquisition, and weak collaboration.

Despite an uptick in venture capital funding, Houston's life sciences sector still trails the likes of Silicon Valley and Boston. Programs like CPRIT help keep companies within Texas, while Houston's unique advantages, such as lower living costs and the TMC's presence, can attract investments, but ultimately, to secure necessary capital, stakeholders must cultivate relationships with investors, government agencies, and other funding sources to infuse more money into the Houston ecosystem. And, when individuals try to do this, the rest of the ecosystem must be supportive.

Talent retention and attraction pose another challenge, as Houston competes with well-funded life science hubs offering abundant research institutions and funding opportunities. While Houston boasts numerous educational institutions producing skilled life sciences graduates, many curricula primarily prepare students for academic rather than industry careers, creating a skills and knowledge gap.

Having a lot of experience in academia doesn’t often translate well into the industry, as is demonstrated by many startup founders who struggle to understand the various stakeholder requirements in bringing a life science product to market.

To bridge this, educational institutions should incorporate more industry-oriented courses and training programs, like Rice University’s GMI Program, that emphasize practical skills and real-world applications. Collaborating with local companies for internships, co-op placements, and hands-on experiences can expose students to industry practices and foster valuable connections.

For any life science company, navigating the intricate regulatory landscape is also a challenge, as missteps can be disastrous. However, it’s even more of a challenge when you lack the fundamentals knowledge of what is required and the skills to effectively engage with industry experts in the space.

To address this, Houston must provide more opportunities for companies to learn about regulatory complexities from experts. Workshops, accelerators, or dedicated graduate and undergraduate courses focusing on regulatory compliance and best practices can facilitate knowledge and experience exchange between regulatory experts and innovators.

The initial inception of M1 MedTech was the result of a personal experience with a company who didn’t understand the fundamentals for regulatory interactions and didn’t know how to appropriately engage with consultants, resulting in time and money wasted.

Enhancing collaboration among Houston's life science stakeholders — including academia, research institutions, healthcare providers, subject matter experts, innovators, and investors — is fundamental for growth. A robust and lively professional network can stimulate innovation and help emerging companies access essential resources.

To this end, Houston should organize more industry-specific events, workshops, and conferences, connecting key life science players and showcasing the city's commitment to innovation. These events can also offer networking opportunities with industry leaders, attracting and retaining top talent. We’ve seen some of this with the Texas Life Science Forum and now with the Ion's events, but we could afford to host a lot more.

Houston's life sciences sector holds immense growth potential, but addressing funding, talent recruitment, regulatory navigation, and collaboration challenges is needed for continued success. By tackling these issues and leveraging its unique strengths, Houston can establish itself as a significant player in the global life sciences arenas. If we wait too long, we won’t be able to truly establish the Third Coast because another player will come into the mix, and we’ll lose companies like BioMatrix to their golden shores.

------

Isabella Schmitt is the director of regulatory affairs at Proxima Clinical Research and principal at M1 MedTech.

Five companies have been selected for a brand new accelerator program in Houston. Image via Getty Images

Houston medtech accelerator announces inaugural cohort

future of health care

A Houston medical technology organization has announced the inaugural cohort of a new early-stage accelerator.

M1 MedTech, launched this year by Houston-based Proxima Clinical Research, announced its Fall 2022 cohort.

“This initial cohort launches M1 MedTech with an interactive 14-week agenda covering the basics every emerging MedTech business needs to progress from a startup to an established solution in their market,” says Sean Bittner, director of programs at M1 MedTech, in a news release.

The accelerator will equip early-stage startups with storytelling, business plan support, investor connections, FDA guidance, research, and more through one-on-one consultations, workships, and in-kind services.

The first cohort includes five startups, per the release from the company:

  1. Linovasc. Providing a long overdue major update to balloon angioplasty devices in over 50 years, the Linovasc solution offers a safer branch occlusion and aortic stent dilatation using a toroidal balloon that expands the aorta uniformly without the ischemia caused by current treatments. The company is founded by Bruce Addis.
  2. Grapheton. Founded by Sam Kassegne and Bao Nguyen, Grapheton's patented carbon materials work with electrically active devices to improve the longevity and outcome of bioelectric implants in the body. Terry Lingren serves as the CEO of the startup.
    • Rhythio Medical. Founded by Kunal Shah and Savannah Esteve, Rhythio is the first preventative approach to heart arrhythmias.The chief medical officer is Dr. Mehdi Razavi.
      • PONS Technology. An AI cognitive functioning ultrasound device attempting to change the way ultrasound is done, PONS is founded by CEO: Soner Haci and CTO: Ilker Hacihaliloglu.
        • Vivifi Medical. Founded by CEO Tushar Sharma, Vivifi is the first suture-less laparoscopic technology that connects vessels to improve male infertility and benign prostatic hyperplasia. The company's senior R&D engineer is Frida Montoya.

          The program includes support from sponsors and experts from: Proxima Clinical Research, Greenlight Guru, Medrio, Galen Data, Merge Medical Device Studio, Venn Negotiation, Engagement PR & Marketing, Aleberry Creative, and others.

          “This is an amazing opportunity for emerging founders to learn the progression of pipelining their ideas through the FDA and absorb the critical strategies for success early in their business development,” says Isabella Schmitt, principal at M1 MedTech and director of regulatory affairs at Proxima CRO, in the release.

          Proxima Clinical Research has its New Year's resolution and is ready to start working hands on with health tech startups. Graphic via proximacro.com

          Houston organization plans to launch health tech accelerator in 2022

          ready to grow

          A contract research organization based in Houston has announced its new accelerator program aimed at helping startups quickly grow their health tech businesses.

          Proxima Clinical Research released details of M1 MedTech, which expects to launch early next year. The CRO has raised funds to launch and invest in members of the inaugural cohort.

          “Our goal is to move these companies substantially forward in a short amount of time,” says Kevin Coker, CEO of Proxima, in a news release. “Proxima is in a unique position to leverage our experienced team of regulatory, quality, and clinical experts. We won’t be working at arm’s length from these companies. We will be a big part of what they do every day.”

          The program will focus on a small group of companies and the Proxima team will provide hands-on support, including instruction, workshops, and one-on-one mentoring.

          “This will be a unique experience for all parties involved, as Proxima is also a young, yet established, company that is now creating a program to assist companies at an earlier stage,” says Larry Lawson, co-founder of Proxima, in the release. “Our experience in the CRO realm and ability to provide coaching in clinical, regulatory, quality, and go-to-market strategies will only strengthen M1 MedTech’s ability to support the success of emerging companies and provide more life-saving technology to the public.”

          Kevin Coker and Larry Lawson co-founded Proxima in 2017. Photos courtesy

          The accelerator will target Class II and III medical devices for its initial cohort. In the future, Proxima plans to expand to include an even more extensive incubator focused solely on Class III devices, according to the release.

          “M1 will be a place where startups can go to receive concrete resources to further their development. The participant success is our sole focus, and the ultimate goal is to have a substantial impact on the ideation-to-market process for Class II and Class III medical devices,” says Isabella Schmitt, director of regulatory affairs at Proxima and a principal at M1, in the release. “Proxima’s specific expertise alongside our M1 partners will provide resources for all key areas of a medical device entrepreneur’s journey to market and beyond.”

          The M1 MedTech applications will open online in the spring.

          “We don’t view M1 as competitive to other accelerators, rather we believe it will offer a different experience. Our team will strive to create a personalized program where companies have a dedicated touch point throughout the process,” says Sean Bittner, director of programs at M1 MedTech, in the release. “We will also provide specific, tailored connections and resources vetted by our team through professional partnerships, not just a general list of industry contacts.”

          One way to move the needle on developing femtech, according to this expert, is to make sure women have a seat at the table at venture firms funding the innovations. Photo via Getty Images

          The growing femtech industry needs more attention — and funds, says this Houston expert

          guest column

          Femtech is a term that is generally given to medical products, software, and technologies that aim to enhance the health and wellbeing of women. But when people think of femtech, things like period tracker apps and pregnancy tests are usually the first things to come to mind. While those developments are important and used regularly, there are other diseases and chronic issues affecting women that need to be talked about as well.

          The concept of femtech shouldn't replace "women's health" which considers broader issues, such as endometriosis and PCOS, as well as other conditions — such as heart disease — common to both men and women but clinically different in the latter. Femtech investors, manufacturers, and health advocates should focus on creating solutions for all issues and diseases that affect women, not just the most obvious.

          However, more education and awareness is necessary to bring these issues to the forefront, as many people are not aware about how certain chronic issues and diseases affect women differently than they may affect men. For example, heart disease is the leading cause of death in women and men, but if you close your eyes and envision someone having a heart attack — do you see a man? Or a woman? Probably a man. And you're not alone. Because so much of our healthcare research has focused primarily on men, we are programmed to think of certain conditions affecting men predominantly when they are truly major health issues for both.

          Similarly, when it comes to memory loss, women have a 1 in 5 chance of developing Alzheimer's disease compared to men being 1 in 11. Additionally, out of the more than 5 million people living with Alzheimer's in the U.S., 3.2 million are women. While there aren't as many Femtech-related products or solutions focused on these issues, there should be, especially in a rapidly growing industry.

          According to the U.S. Clinical Laboratory Test Market, the femtech industry is expected to grow at a compound annual growth rate of more than 13 percent. Frost and Sullivan predicts the global Femtech market revenue will reach $1.1 billion by 2024, and BIS Research forecasts that by 2030 the sector will hit $3.04 billion. But even with great momentum, there is a knowledge gap that needs to be bridged. Overall, the industry has been underfunded and many opportunities have been overlooked, not necessarily because of gender. But, because investors in the industry are predominantly men, there is a lack of education and understanding of why these products are needed.

          A solution would be for more women to become investors. Women have the personal experience and a better understanding of how these products will benefit them, which allows them to better understand the story told, increasing the chance the product will be funded and brought to market. To fund life-changing inventions for women, we need to have women involved, which means we need women to step into the investment community. Until more women get a seat at the investment table, women in femtech who are looking for investors need to be prepared to share real life stories and provide as much information as possible to have a better chance of securing funding.

          The femtech industry is growing, and we will continue to see innovative devices and apps brought to market. With more education, a better understanding of other issues that affect women, and more female investors, the industry has the potential to take its growth to a new level.

          ------

          Isabella Schmitt currently serves as the director of regulatory affairs at Proxima Clinical Research Inc.
          Ad Placement 300x100
          Ad Placement 300x600

          CultureMap Emails are Awesome

          Houston Innovation Awards opens ticket sales as nomination deadline looms

          mark your calendar

          You can now buy tickets to the 2023 Houston Innovation Awards on November 8 — but the deadline to nominate deserving individuals and companies for the prestigious awards is just a few days away.

          Tickets are available online for the awards event taking place at Silver Street Studios, and InnovationMap has a few options to choose from. Individual tickets are on sale for $80, with a special founder price of $40 available. This year, individual tickets will have seating at a first come, first served basis, but attendees are also able to opt into a reserved table of 10 for $1,000. Sponsors, judges, and finalists and their guests will receive complimentary tickets.

          The nomination period for the annual awards is coming to a close next week on Tuesday, September 19. Click here to read about this year's awards categories.The process includes submitting nominations on behalf of yourself or others, and next week, nominees will be sent an application that will be due October 4. A panel of judges will review the applications and finalists will be announced and notified ahead of the event.

          If you are interested in joining our partners, which include The Ion, Uncle Nearest Premium Whiskey, Tito’s Handmade Vodka, and more, in sponsoring this event, please reach out to misti@gowmedia.com.

          Secure your Houston Innovation Awards tickets now.

          Submit a nomination before it's too late!

          Cultivating an office culture can prevent loneliness, create connections, says Houston expert

          guest column

          There’s been a lot of chatter about returning to the office and remote work. No matter which side of the argument you’re on, there are valid points to be made for both views. The pandemic forced organizations to rethink operations, with many employees working remote for the first time. And now, we’re in that habit and many don’t want to change.

          But here’s the thing. Isolation creates loneliness and we’re in the middle of a loneliness epidemic. A report released by The U.S. Surgeon General titled “Our Epidemic of Loneliness and Isolation,” found that even before COVID changed the world, about half of the U.S. adults reported experiencing measurable levels of loneliness. While technology has allowed for work to continue outside of traditional office walls by dialing in to video conferences from home, there is still a missing link. It’s much harder to build community virtually. We haven’t cracked that code yet.

          Sen. Chris Murphy, D – Conn, recently introduced legislation to create a national policy to promote social connection and address the soaring rates of loneliness.

          “Loneliness is one of the most serious, misunderstood problems facing America today,” Murphy said in a press statement. “This crisis transcends traditional political boundaries, presenting a chance to bring together right and left around a project to help people find connectedness.”

          Whether people realize it or not, we all need to feel seen and understood, and when that happens it creates meaningful connection. That connection in turn leads to strong company Whether people realize it or not, we all need to feel seen and understood, and when that happens it creates meaningful connection. That connection in turn leads to strong company culture and more productive, energizing workdays.

          Happiness begins with healthy human relationships and companies are being challenged to balance employee flexibility and workplace interactions. While there is no clear-cut right answer, Birkman International is moving to a four-day, in-office workweek. Employees will cut back from 40 to 32 hours-per-week and those hours will be spent at Birkman’s offices.

          With employees once again working under the same roof, there will be opportunities for organic spot meetings, team brainstorms and water cooler chatter. While some might see these as “soft” skills, they are essential for a well-performing workplace.

          It’s important to remember that there’s no one-size-fits-all solution to balancing employee flexibility with returning to the office. Just like every person has unique needs, every company must figure the best solution for its culture, its productivity and most importantly, its people.

          ------

          Amy Shepley serves as president at Birkman International, an industry-leading organizational performance company.

          Houston startup with sustainable biotech solutions lands offtake arrangement with United Airlines

          ready for takeoff

          An innovative Houston company is celebrating a new deal with a global airline.

          Cemvita Corp. announced a new offtake arrangement with United Airlines. Cemvita's first full-scale sustainable aviation fuel plant will provide up to 1 billion gallons of SAF to United Airlines. The 20-year contract specifies that Cemvita will supply up to 50 million gallons annually to United.

          It's not the first collaboration Cemvita has had with the airline. Last year, United invested in the biotech company, which used the funding to open its Houston pilot plant.

          “Since our initial investment last year, Cemvita has made outstanding progress, including opening their new pilot plant – an important step towards producing sustainable aviation fuel,” United Airlines Ventures President Michael Leskinen says in a news release. “United is the global aviation leader in SAF production investment, but we face a real shortage of available fuel and producers. Cemvita’s technology represents a path forward for a potentially significant supply of SAF and it’s our hope that this offtake agreement for up to one billion gallons is just the beginning of our collaboration.”

          Founded in Houston in 2017 by brother-sister team Moji and Tara Karimi, Cemvita's biotechnology can mimic the photosynthesis process, turning carbon dioxide into feedstock. The company's SAF plan hopes to increase reliability of existing SAFs and lower impact of fuel creation.

          “Biology is capable of truly amazing things,” Moji Karimi, CEO of Cemvita, says in the release. “Our team of passionate, pioneering, and persistent scientists and engineers are on a mission to create sustainable BioSolutions that redefine possibilities.”

          “We are thrilled to partner with United Airlines in working towards transforming the aviation industry and accelerating the energy transition,” he continues. “This agreement featuring our unique SAF platform is a major milestone towards demonstrating our journey to full commercialization.”

          Earlier this year, United, which was reportedly the first airline to announce its goal of net zero carbon emissions by 2050, launched its UAV Sustainable Flight FundSM. The fund, which named Cemvita to its inaugural group of portfolio companies, has raised over $200 million, as of this summer.

          Moji and Tara Karimi co-founded Cemvita in 2017. Photo courtesy of Cemvita

          ------

          This article originally ran on EnergyCapital.